Clinical Trial: NCT03381768
Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Lars Møller Pedersen |
| Information Provided By: | Herlev Hospital |
| Last Update Posted: | 2021-02-24 |
Study Overview
Brief Summary
An open phase-1, first-in-human, clinical trial investigating the safety and immunological effects of peptide vaccination with Programmed Death Ligand 1 and 2 (PD-L1 and PD-L2) peptides in patients with relapsed follicular lymphoma.
Official Title
PD-L1 and PD-L2 Peptide Vaccination as Consolidation for Relapsed Follicular Lymphoma
Conditions
Follicular Lymphoma
Intervention / Treatment
- Biological: PD-L2 peptide
- Biological: PD-L2 and PD-L1 peptide
Other Study ID Numbers
- FL1701
- 2017-002000-28
- 2017
Start Date (Actual)
2017-12-12
Primary Completion Date (Actual)
2020-02-12
Study Completion Date (Actual)
2020-02-12
Enrollment (Actual)
8
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Lars Møller Pedersen |
| Information Provided By: | Herlev Hospital |
| Last Update Posted: | 2021-02-24 |
Study Overview
Brief Summary
An open phase-1, first-in-human, clinical trial investigating the safety and immunological effects of peptide vaccination with Programmed Death Ligand 1 and 2 (PD-L1 and PD-L2) peptides in patients with relapsed follicular lymphoma.
Official Title
PD-L1 and PD-L2 Peptide Vaccination as Consolidation for Relapsed Follicular Lymphoma
Conditions
Follicular Lymphoma
Intervention / Treatment
- Biological: PD-L2 peptide
- Biological: PD-L2 and PD-L1 peptide
Other Study ID Numbers
- FL1701
- 2017-002000-28
- 2017
Start Date (Actual)
2017-12-12
Primary Completion Date (Actual)
2020-02-12
Study Completion Date (Actual)
2020-02-12
Enrollment (Actual)
8
Study Type
Interventional
Phase
Phase 1